NCT06903754Completed
ISGLT2 in Patients Without DM With Acute MI
Sodium Glucose Cotransporter 2 Inhibitors in Patients Without Diabetes With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Source: ClinicalTrials.gov · Last updated 15 Sept 2025
Brief summary (registry, in English)
This study will evaluate the effect of ISGLT2 (Dapagliflozin or Empalgliflozin), administered once daily in addition to standard of care treatments for non-diabetic patients with myocardial infarction (MI) treated with PCI, on hospitalization for heart failure, readmissions for acute coronary syndrome and all-cause mortality.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 450 (actual)
- First submitted
- 22 Mar 2025
- Start date
- 1 Oct 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Mohammed VI University Hospital
- Diseases
- Heart failure, Coronary artery disease
- NCT number
- NCT06903754
What you commit to
- Study type: Observational
- Participants enrolled: 450
- From 1 Oct 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients with cardiogenic shock who received vasoactive drugs during index.
Other illness
- Known type 1 diabetes mellitus (T1DM) or T2DM at the time for admission.
- Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the trial.
- Active malignancy requiring treatment at the time of screening.
- Any non-CV condition, eg malignancy, with a life expectancy of less than one years based on the investigator´s clinical judgement.
Lab values
- Chronic symptomatic HF with a prior HHF within the last year and known reduced ejection fraction (LVEF≤40 %), documented before the current MI hospitalization.
- Hospitalization Severe (eGFR \<20 mL/min/1.73 m2 by local laboratory), unstable or rapidly progressing renal disease at the time of randomization
- Currently on treatment, or with an indication for treatment, with a sodium glucose co-transporter 2 inhibitor (SGLT2-inhibitor)
Who the study is looking for
- Participant must approved the informed consent.
- Confirmed MI, either STEMI or NSTEMI, according to the fourth universal definition of MI (Thygesen et al 2019).
- Evidence of impaired regional or global LV systolic function at any timepoint during current MI-related hospitalisation with Ejection Fraction\<50%(established with echocardiogram, radionuclide ventriculogram, contrast angiography or cardiac MRI) or Symptoms of Acute heart failure without cardiogenic Shock.
- Hemodynamically stable (no episodes of symptomatic hypotension, or arrhythmia with haemodynamic compromise in the last 24 hours).
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mohammed VI university hospital oujda Coordinator of this site? Confirm its status | OUDA | Morocco | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.